Amrutanjan Health Care's Q3 Financial Performance

Amrutanjan Health Care, a smallcap pharmaceutical company, recently declared its financial results for the quarter ended September 2023. The stock call by MarketsMOJO for the company is 'Sell'. According to the quarterly analysis, the company has seen a 27.55% growth in net sales compared to the previous quarter, but a -2.28% decline in standalone net profit. The operating profit (PBDIT) excluding other income has also decreased by -4.34%. However, the interest has increased by 50% in the same period. The operating profit margin (excluding other income) has fallen from the previous quarter, indicating a negative financial performance for Amrutanjan Health Care in the quarter ended September 2023. The overall score for the company has also fallen from 0 to -11 in the last three months. Despite the negative performance, there are some positive aspects for Amrutanjan Health Care based on the September 2023 financials. The company has consistently distributed higher dividends from its profits, with the dividend per share (DPS) being the highest in the last five years at Rs 4.60. The dividend payout ratio (DPR) has also been the highest in the last five years at 33.75%, indicating that the company is distributing a higher proportion of its profits as dividends. However, there are some areas of concern for the company. The profit before tax (PBT) less other income has fallen by -63.45% year on year, and the operating cash flow has also decreased each year in the last three years. The net sales have also declined by -10.31% year on year, and the operating profit (PBDIT) is at its lowest in the last five quarters. The operating profit margin has also decreased, indicating a decline in the company's efficiency. The non-operating income is also high, which is not a sustainable business model. The earnings per share (EPS) have also decreased, showing a decline in profitability and lower earnings for shareholders. In conclusion, Amrutanjan Health Care has seen a negative financial performance in the quarter ended September 2023, with some positive aspects but also some areas of concern. Investors should carefully consider these factors before making any investment decisions.